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ARTICLE OPEN
Morning and night symptoms in primary care COPD patients:
a cross-sectional and longitudinal study. An UNLOCK study
from the IPCRG
Ioanna Tsiligianni1,2, Esther Metting1,2, Thys van der Molen1,2, Niels Chavannes3 and Janwillem Kocks1,2
COPD symptoms show a diurnal variability. However, morning and night variability has generally not been taken into consideration
in disease management plans. The aims of this study were to cross-sectionally assess morning and night symptom prevalence and
correlation with health status and disease severity in COPD, and to determine to what extent they could predict longitudinal
outcomes, exacerbations and health status. A further aim is to explore whether the CCQ is able to depict this morning/night
symptomatology. We included 2,269 primary care COPD patients (58% male, 49% current smokers, with a mean age of 65 ± 11
years) from a Dutch Asthma/COPD service. Spirometry, patient history, the Clinical COPD Questionnaire(CCQ) and the Asthma
Control Questionnaire(ACQ) were assessed; we used the latter to evaluate morning (question 2) and night symptoms (question 1).
A total of 1159 (51.9%) patients reported morning symptoms (ACQ question 240) and 879 (39.4%) had night complaints
(ACQ question 140). Patients with morning/night symptoms were mostly smokers and had on average poorer lung function,
higher CCQ scores and used more rescue inhalers (Po0.0001). Patients using long-acting muscarinic antagonists (LAMAs) had less
night symptoms, showing a possible favourable effect. Only a small proportion of stable or slightly unstable patients (CCQ total
scores o2) had severe morning symptoms (ACQ 2⩾ 4: n= 19, 1.1%) or severe night symptoms (ACQ 1⩾ 4: n= 11, 0.7%). Night
symptoms seemed to predict future exacerbations; however, baseline exacerbations were the strongest predictors (n= 346, OR:4.13,
CI: 2.45− 6.95, Po0.000). Morning symptoms increased the odds of poor health status at follow-up (n= 346, OR:12.22,
CI:4.76− 31.39, Po0.000). Morning and night symptoms in COPD patients are common, and they are associated with poor health
status and predicted future exacerbations. Our study showed that patients with morning/night symptoms have higher scores in
CCQ, and therefore we do not really miss patients with high morning/night symptomatology when we only measure CCQ. Severe
morning symptoms predicted worsening of COPD health status.
npj Primary Care Respiratory Medicine (2016) 26, 16040; doi:10.1038/npjpcrm.2016.40; published online 21 July 2016
INTRODUCTION
Chronic obstructive pulmonary disease is a progressive disease
characterised by persistent airﬂow limitation associated with
substantial morbidity and mortality.1 The primary symptoms of
the disease are dyspnoea, cough and sputum production.1
Starting in 2011, until the latest revision of GOLD 2015, pulmonary
function, symptoms/health status assessment (as assessed
by mMRC, CAT or CCQ)2–4 and number of exacerbations are
included in the COPD algorithm for patient classiﬁcation and
management.1
Recognising the importance of the severity of symptoms,
patients are categorised in the A,C (few symptoms) or B,D (more
symptoms) categories.1 Next, a measure of risk is included in the
algorithm. Both low lung function (forced expiratory volume
in 1 s (FEV1) below 50% of predicted) or previous exacerbations
(more than 2 in the last year or a hospital admission) result in
classiﬁcation in high risk (C,D).1 The classiﬁcation in A–D will lead
to management suggestions in the GOLD guideline.
Consequently, the decision tree for management is based
on this classiﬁcation. With this categorisation, GOLD
recommendations attempt a more personalised approach to
disease management.1 Symptom assessment is included in the
three questionnaires used by GOLD (CAT, mMRC and CCQ) and in
most patient-reported outcome questionnaires. However, none of
them include a speciﬁc question for diurnal symptom variability,
morning or night.1–5 CAT has a question on sleep, but it only
assess whether the patient sleeps soundly or not.3 GOLD
guidelines do not mention morning and night-time symptoms
as targets for therapeutic interventions, and they do not offer a
speciﬁc guidance on appropriate management strategies or
pharmacological interventions for patients with COPD who report
diurnal variability in their symptoms.1,6 Moreover, it appears that
patients do not report symptom variability and do not modify
treatment when symptoms worsen,6,7 and thus physicians are
unlikely to discuss diurnal variability with patients.6,8
Not only asthma but also COPD shows diurnal variability in
physiological spirometric parameters of lung function and peak
expiratory ﬂow (PEF).9,10 Recent studies have shown that COPD
symptoms follow physiological diurnal variability and vary over
time,7,11–13 as well as by geographical areas.7 Morning7,11–18 and
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night symptoms6,7,13,19–23 are prevalent and burdensome for
patients with COPD, compromising patients’ ability to perform
tasks throughout the day.7,8,11–15,24 It seems that patients
experience the biggest increase in respiratory symptoms during
the early hours of the morning, followed by another increase in
the night time,11,13,16 especially in patients with severe COPD.13,15
This coincides with the circadian variation in lung function. In
particular, morning symptoms have been found to be associated
with worse health status,13,18 sleep quality,13 higher anxiety and
depression,13 and more exacerbations.7,18 In the same way, night
symptoms are associated with worse health status13,19 and seem
to be able to predict future exacerbations.20 However, most of the
studies concerning the variability of symptoms have only assessed
morning or night symptoms in speciﬁc groups of COPD patients.
Therefore, the aims of our study were to explore the prevalence
of morning and night symptoms, their distribution in different
GOLD stages and grades and their correlation with lung function
and health status, as well as to longitudinally explore their role in
predicting future events such as worsening of health status and
exacerbations. The null hypothesis was that morning and/or night
symptoms were a distinct phenotype of highly symptomatic
patients not captured by CCQ.
We conducted this study in a real-life setting with the aim of
having a high external validity, as a primary care population has
been used. Moreover, we aimed at assessing both morning and
night symptoms rarely assessed simultaneously, as previously
mentioned, in other studies.
RESULTS
Descriptive analyses
In our COPD population (n= 2269), 1,159 (51.9%) and 879 (39.4%)
patients reported morning symptoms and night symptoms,
respectively. Sociodemographic and baseline characteristics of
the COPD patients are depicted in Table 1. A subset of patients
had severe morning and night symptoms, with n= 109 (4.9%) and
n= 74 (3.3%), respectively (Table 1). Only a small proportion of
patients with stable or slightly unstable COPD (CCQ total
scoreso2) had severe morning symptoms (ACQ 2⩾ 4: n= 19,
1.1%) or severe night symptoms (ACQ 1⩾ 4: n= 11, 0.7%; Table 1).
The correlation between morning and night symptoms was
moderate (r= 0.53), as was also their correlation with the CCQ
(r= 0.58, r= 0.52, respectively). More details on correlations are
depicted in Table 2.
Inferential analyses: cross-sectional differences
Patients with morning/night symptoms had on average poorer lung
function, higher CCQ scores, higher disease severity, were mostly
smokers and used more rescue inhalers and less Long-Acting
Muscarinic Antagonists (LAMA) compared with patients without
morning/night symptoms (Table 3). Post hoc tests showed that
patients with only night symptoms used LAMA less frequently
(binominal regression OR =0.50 (0.31–0.80), P value =0.004). We
did not ﬁnd similar effects in other types of medication. The
prevalence of GOLD D in patients without morning or night
symptoms was 8%, whereas 28.9% of the patients with morning and
night symptoms were GOLD D patients (Figure 1). This pattern was
not found in the GOLD 1–4 grades (Table 3, Figure 2), which might
indicate that FEV1 is not related to morning and night symptoms.
Inferential analyses: longitudinal differences
Baseline exacerbations were the strongest predictors of exacer-
bations at follow-up, whereas patients with severe morning and
moderate night symptoms had a higher risk of having an
exacerbation compared with patients without these symptoms
(Table 4). Severe morning symptoms were strong predictors of
Table 1. Sociodemographic and baseline characteristics of the COPD
patients
Variable n total Statistic
Gender and age
Men 2,269 n (%) 1,312 (57.8)
Age 2,269 Mean (s.d.) 65.3 (10.8)
Age of onset 1,992 Mean (s.d.) 52.4 (19.7)
Exacerbations 2,263 Mean (s.d.) 0.72 (1.1)
Lung function post bronchodilator
FEV1 (l) 2,262 Mean (s.d.) 2.0 (0.7)
FEV1% predicted 2,263 Mean (s.d.) 69.3 (18.0)
FVC (l) 2,210 Mean (s.d.) 3.5 (1.0)
FVC % predicted 2,211 Mean (s.d.) 98.8 (18.4)
FEV1 / FVC 2,260 Mean (s.d.) 56.1 (11.0)
Reversibility 2,063 Mean (s.d.) 6.2 (8.0)
Smoking history (age⩾ 18 years) 2,261
Never smoked n (%) 80 (3.5)
Ex-smoker n (%) 1,069 (47.1)
Current smoker n (%) 1,112 (49.0)
Smoking history missing n (%) 8 (0.4)
GOLD stage
GOLD 1 (FEV1480%) 2,269 n (%) 670 (29.5)
GOLD 2 (50%oFEV1o80%) n (%) 1,257 (55.4)
GOLD 3 (30%oFEV1o50%) n (%) 317 (14.0)
GOLD 4 (FEV1o30%) n (%) 25 (1.1)
GOLD A 2,264 n (%) 646 (28.5)
GOLD B n (%) 916 (40.4)
GOLD C n (%) 176 (7.8)
GOLD D n (%) 526 (23.2)
GOLD ABCD missing n (%) 5 (0.2)
Patient-reported outcomes
ACQ question 2: morning
symptoms
2,231 Mean (s.d.) 1.1 (1.3)
Symptomatic (ACQ 2⩾ 1) n (%) 1,159 (51.9)
Severe symptoms (ACQ 2⩾ 4) n (%) 109 (4.9)
Of which stable or slightly
unstable COPD patients
(CCQo2)
109 n (%) 19 (1.1)
ACQ question 1: night
symptoms
2,233 Mean (s.d.) 0.7 (1.1)
Symptomatic (ACQ 1⩾ 1) n (%) 879 (39.4)
Severe symptoms (ACQ 1⩾ 4) n (%) 74 (3.3)
Of which stable or slightly
unstable COPD patients
(CCQo2)
74 n (%) 11 (0.7)
Clinical COPD questionnaire
total score (CCQ)
2,263 Mean (s.d.) 1.4 (1.0)
Stable (CCQo1) n (%) 817 (36.0)
Not entirely stable (CCQ⩾ 1
ando2)
n (%) 869 (38.3)
Unstable (CCQ⩾ 2 and o3) n (%) 391 (17.2)
Very unstable (CCQ⩾ 3) n (%) 177 (7.8)




Controlled (ACQ o0.75) n (%) 848 (37.4)
Partially controlled (ACQ⩾ 0.75
and o1.50)
n (%) 625 (27.5)
Uncontrolled (ACQ⩾ 1.50) n (%) 753 (33.2)
ACQ missing n (%) 43 (1.9)
Abbreviations: ACQ, Asthma Control Questionnaire; CCQ, COPD Clinical
Questionnaire; COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global initiative
for chronic obstructive disease.
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poor health status. This relationship was even stronger than the
predictive value of baseline health status on health status at
follow-up. Morning or night symptoms did not predict FEV1%
predicted at follow-up (Table 4).
DISCUSSION
Main ﬁndings
Our study showed that morning and night symptoms were common
in real-life primary care COPD patients. Patients with morning/night
symptoms had on average poorer lung function, higher CCQ scores
and most of them were smokers. Only a small proportion of patients
with stable or slightly unstable COPD (CCQ total scores o2) had
severe morning symptoms (ACQ 2⩾4: n=19, 1.1%) or severe night
symptoms (ACQ 1⩾4: n=11, 0.7%), rejecting our null hypothesis
that morning and/or night symptoms were a distinct phenotype of
highly symptomatic patients not captured by CCQ.
This is extremely important, as it shows that patients with
morning/night symptoms do not represent a distinct phenotype.
Morning/night symptoms predicted the number of exacerbations
in the following 10–17 months, but the effect disappeared after
adding baseline exacerbations in the model. Severe morning
symptoms were more strongly predictive of health status than
night symptoms at follow-up. Morning or night symptoms did not
predict FEV1 decline within a year.
Interpretation of ﬁndings in relation to previously published work
Morning/night symptoms: prevalence and correlations. Our study
showed that morning (51.9%) and night symptoms (39%) were
common in COPD patients (Tables 1 and 3) in accordance with
several studies that showed that symptoms are worse in the
morning.7,8,11,12,13,15,18 However, studies show a great heteroge-
neity in results because of differences in COPD populations, the
study design, the ways to measure these symptoms and their
severity. Therefore, some studies showed lower prevalence than
our study in morning symptoms (37%–46% depending on GOLD
severity12,18), whereas other studies have shown higher preva-
lence than our study,7,13,15 with prevalences that reached
higher than 65% for some symptoms such as morning
breathlessness.7,12,13 In our study, night symptom prevalence
reached the 39% of patients with COPD. Partridge et al.12 reported
night-time symptoms to be around 25–34% depending on
severity, whereas a higher rate reaching 68% was reported in
another study.19 In the study by Lange et al., in which a very large
cohort of COPD patients (n= 6,616) was examined, the prevalence
of night-time dyspnoea was 4%, increasing to 9% and 16% in
severe and very severe patients, respectively.20
In our study, 32.04% of patients had both morning and night
symptoms, conﬁrming the ﬁndings of the ASSESS study, which
showed that only 10.6% of patients had symptoms in only one
part of the day, whereas the majority had both morning and night
symptoms.13 Correlations of morning and night symptoms
between them was modest (r= 0.53), suggesting that they may
measure a different concept.
Morning/night symptoms: gender and smoking. We did not ﬁnd
gender differences regarding morning/night symptoms, which is
in concordance with the study from Roche et al.18
The proportion of smokers was higher in patients with morning
and/or night symptoms. Patients experiencing morning symptoms
were more likely to be current smokers as in the study by Roche
et al.18 In our study, the pattern was completely the opposite in
patients who quit smoking at least 12 months earlier, as the
majority of them no longer reported morning and night
symptoms, conﬁrming the beneﬁts of smoking cessation.
Morning/night symptoms and lung function. Patients with morning
or/and night symptoms had on average poorer lung function (FEV1,
FEV1/FVC). In the same way in the Roche et al study, patients with
morning symptoms had worse lung function.18 In our study, the
correlation between both morning and night symptoms with lung
function (Table 2) was low, conﬁrming that symptoms in general do
not correlate well with lung function, which is already known.1
Moreover, our longitudinal analysis showed that morning symptoms
or night symptoms did not predict FEV1 decline in 1 year (Table 4).
Morning/night symptoms and disease severity. Differences existed
between the four categories (patients with both morning and
Table 2. Correlations between symptoms and patient characteristics
n Morning symptomsa Night symptomsb
r Proportion explained variance (r2) r Proportion explained variance (r2)
Characteristics
Age 2,233 − 0.12 1% − 0.1 1%
Age of onset 1,992 − 0.05 0% − 0.02 0%
FEV1 predicted 2,227 − 0.16 3% − 0.1 1%
FEV1/FVC predicted 2,224 − 0.11 1% − 0.03 0%
Mean number of exacerbations last year 2,228 0.13 2% 0.12 1%
Symptoms
Night symptoms (ACQ question 1) 2,233 0.53 28% 1 100%
Morning symptoms (ACQ question 2) 2,231 1 100% 0.53 28%
Sputum production (CCQ question 6) 2,231 0.46 21% 0.39 15%
Wheezing (ACQ question 5) 2,232 0.45 20% 0.44 19%
Health status
CCQ subscale functional status 2,233 0.44 19% 0.39 15%
CCQ subscale mental status 2,230 0.41 17% 0.39 15%
CCQ subscale symptoms 2,232 0.59 35% 0.52 27%
CCQ total scale 2,229 0.58 34% 0.52 27%
Abbreviations: ACQ, Asthma Control Questionnaire; CCQ, COPD Clinical Questionnaire; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity.
aACQ question 2.
bACQ question 1.
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night symptoms, any or none of these symptoms) within the
different GOLD stages (I, II, III and IV) and A,B,C,D categories
(Table 3, Figures 1 and 2). However, only a low number of patients
with low symptomatology according to CCQ had high morning
symptoms/night symptoms (1.5% and 0.7%, respectively),
demonstrating that CCQ does capture the morning/night
symptomatology well. Two studies have shown a signiﬁcant
association between night-time symptoms and the severity of
airﬂow obstruction in patients with COPD;19,20 however, our study
was in accordance with the study of Miravittles et al.,13 showing
that the prevalence of night-time symptoms was comparable
across all severities of airﬂow limitation. These data suggest that
the presence of night-time symptoms is not merely a conse-
quence with severe airﬂow limitation.
The pattern of morning and/or night symptoms was better
represented in the A,B,C,D categories (Figure 1) than in GOLD
Table 3. Differences in characteristics between patients with no morning and night symptoms, only morning or night symptoms and patients with











n= 908 n=444 n= 164 n= 715
Characteristics
Age Mean (s.d.) 65.9 (0.4) 63.2 (0.6) 64.8 (0.9) 65.4 (0.6) o0.000
Age of onset Mean (s.d.) 52.9 (0.8) 50.1 (1.2) 54.9 (1.4) 53.8 (1.1) NS
Male n (%) 495 (58.9) 188 (56.5) 74 (54.4) 203 (57.5) NS
Exacerbations Mean (s.d.) 0.6 (1.0) 0.8 (1.2) 0.6 (0.9) 0.9 (1.0) o0.000
FEV1/FVC post-proportion predicted n (%) 57.3 (10.7) 54.2 (11.4) 55.9 (10.6) 55.7 (11.1) o0.000
FEV1 post-proportion predicted n (%) 72.1 (17.4) 66.6 (17.8) 69.7 (19.2) 67.2 (18.2) o0.000
Smoking
Current smoker n (%) 316 (37.6) 194 (58.3) 71 (52.2) 203 (57.5) o0.000
Never smoker n (%) 29 (3.5) 7 (2.1) 3 (2.2) 16 (4.5)
Quit ⩾ 12 months ago n (%) 493 (58.7) 131 (39.3) 62 (45.6) 134 (38.0)
Clinical COPD Questionnaire(CCQ)
Subscale functional status Mean (s.d.) 0.6 (0.0) 0.9 (0.0) 0.9 (0.1) 1.0 (0.0) o0.000
Subscale mental status Mean (s.d.) 0.1 (0.0) 0.2 (0.0) 0.3 (0.1) 0.5 (0.0) o0.000
Subscale symptom status Mean (s.d.) 1.3 (0.0) 1.8 (0.0) 1.8 (0.1) 2.2 (0.0) o0.000
Total score Mean (s.d.) 0.8 (0.0) 1.1 (0.0) 1.1 (0.0) 1.4 (0.0) o0.000
Symptoms
Sputuma Mean (s.d.) 1.1 (0.0) 1.9 (0.1) 1.7 (0.1) 2.5 (0.1) o0.000
Wheezingb Mean (s.d.) 0.8 (0.0) 1.3 (0.1) 1.3 (0.1) 1.9 (0.1) o0.000
Exacerbationsc Mean (s.d.) 0.6 (1.0) 0.8 (1.2) 0.6 (0.9) 0.9 (1.0) o0.000
GOLD Stage
1 n (%) 299 (35.6) 50 (36.8) 50 (36.8) 121 (34.3) o0.000
2 n (%) 470 (56.0) 68 (50.0) 68 (50.0) 189 (53.5)
3 n (%) 68 (8.1) 17 (12.5) 17 (12.5) 41 (11.6)
4 n (%) 3 (0.4) 1 (0.7) 1 (0.7) 2 (0.6)
A n (%) 458 (54.5) 84 (25.2) 36 (26.5) 52 (14.7) o0.000
B n (%) 210 (25.0) 130 (39.0) 62 (45.6) 182 (51.6)
C n (%) 104 (12.4) 40 (12.0) 14 (10.3) 17 (4.8)
D n (%) 67 (8.0) 79 (23.7) 24 (17.6) 102 (28.9)
Medication
No medication n (%) 387 (42.6) 164 (36.9) 80 (48.8) 287 (40.1) 0.06
Short-acting bronchodilators n (%) 90 (9.9) 77 (17.3) 24 (14.6) 145 (20.3) o0.000
Inhaled corticosteroids n (%) 68 (7.5) 39 (8.8) 11 (6.7) 52 (7.3) NS
Leukotriene antagonists n (%) 3 (0.3) 1 (0.2) 0 (0.0) 1 (0.1) NS
Short-acting bronchodilator and
anticholinergics
n (%) 2 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) NS




n (%) 277 (30.5) 137 (30.9) 50 (30.5) 206 (28.8) NS
Long-acting muscarinic antagonists n (%) 223 (24.6) 97 (21.8) 23 (14.0) 144 (20.1) 0.012
Short-acting muscarinic antagonists n (%) 67 (7.4) 32(7.2) 12(7.3) 1 (0.1) NS
Oral corticosteroids n (%) 0 (0.0) 2 (0.5) 0 (0.0) 57 (8.0) NS
The total number of patients in this table is 2,231, as 38 patients did not ﬁll in the ACQ.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global initiative for
chronic obstructive disease; NS, not signiﬁcant.
aCCQ question 6.
bACQ question 5.
cDeﬁned as having used antibiotics or oral corticosteroids in the past 12 months for respiratory complaints.
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1,2,3,4 (Figure 2). In an international study, patients in category D
followed by the category B showed the highest rates of night
symptoms, which was similar to our study.19 Our study, however,
took the next step by also showing that morning and morning
plus night symptoms were more prevalent in category D. This in a
sense is expected, as categories B and D are the categories with
more symptomatology.1 However, patients in categories A and C
(low symptoms categories) also had a high rate of morning and/or
night symptoms, similar to another study on night symptoms.19
Similar ﬁndings were also observed in the study by Lange et al.,
which showed a high rate of night-time dyspnoea in descending
rates in D, B, C and A.20
Morning/night symptoms and health status. Patients experiencing
morning and/or night symptoms had worse health status, as
assessed by CCQ. In addition, in other studies, a worse health
status was found when morning symptoms were present, as
assessed either by CAT13,18 or EQ-5D.18 In the same way, a worse
health status was found when night symptoms were present, as
assessed either by CAT13 or EQ-5D.19 In addition, patients with
COPD and poor sleep quality25 or insomnia26 had mentioned a
worse quality of life.
A modest correlation between morning and night symptoms and
CCQ was found, suggesting that they may measure a different
concept and should therefore be taken into consideration when
tailoring treatment and interventions. However, morning symptoms
had a greater correlation and explained in a greater degree the
variance in health status than night symptoms. In addition, only a
small proportion of patients with stable or slightly unstable COPD
(CCQ total scores o2) had severe morning/night symptoms.
Severe morning symptoms and baseline CCQ scores compared
with FEV1 were the strongest predictors of CCQ scores at follow-
up. As health status is included in the COPD GOLD management
algorithm, it would be rational to suggest to clinicians to also
control morning symptoms to avoid worsening of health status.
Morning/night symptoms and exacerbations. In our study,
patients with morning and night symptoms, as well as those with
only morning symptoms, had more exacerbations. COPD symp-
toms ﬁrst thing in the morning have been shown to be
independently associated with more exacerbations.7,18
Our study showed that baseline exacerbations were the strongest
predictors of future exacerbations compared with morning/night
symptoms. It is well known that previous exacerbations may be
considered as a different phenotype showing susceptibility to
exacerbations.27,28 The ECLIPSE study showed that the major
determinant of frequent exacerbations in all GOLD stages of COPD
severity was a history of exacerbations.28 Lange et al. have shown
that nocturnal symptomatic COPD patients had a 2.3-fold higher risk
of suffering a future exacerbation; however, this study assessed only
night-time symptoms, contrary to our study that showed that
morning symptoms were the symptoms that predicted mostly
future exacerbations as compared with night symptoms.20 Omachi
et al.22 also showed that sleep disturbances predict future
exacerbations, mortality and emergency utilisation.
Morning–night symptoms and medication use. In our study,
signiﬁcant differences were observed in short-acting bronchodilators
and LAMA use with morning and night symptoms/only morning/
only night/no morning–night symptoms (in a descending order)
using more SABA. The fact that these patients used more SABA
shows that despite optimum maintenance therapy those patients
still have a need for symptom relief. Similarly, in the study by Kessler
et al , patients with day-time variability used more emergency
inhalers (35.7%).7 In the study by Roche et al, there was an increased
use of maintenance (LABA, LAMA) and combination therapies when
morning symptoms were present.18 Because of the recent
introduction of ﬁxed LABA/LAMA combination, no patients used a
ﬁxed LABA/LAMA combination in one device at the time of analysis.
In our study, no differences in LABA and combination therapies were
found on morning/night symptoms. However, there were great
differences in morning/night symptoms between LAMA users and
those who did not use LABA, showing a possible protective effect. In
the same way, in the study by Kim et al, LAMAs (odds ratio [OR],
6.971; 95% conﬁdence interval, 1.317 to 11.905 Po0.0143) were
identiﬁed as signiﬁcantly related to the absence of morning
symptoms.15 The post hoc analysis in our study, however, showed
that patients using LAMA had less night symptoms, whereas LAMA
was not effective in the patients with morning symptoms. Therefore,
this group of patients with only night symptoms may beneﬁt from
the use of LAMA in the future.
Strengths and limitations of this study
We designed this real-life study using patients from a primary care
population in order to ensure a high external validity. To our
knowledge, it is also the ﬁrst study that assessed longitudinally the
role of both morning and night symptoms in predicting
exacerbations and health status. This study enroled patients
independent of disease severity, from the usual consultations in
Figure 1. Percentages of patients with no morning and night
symptoms, only night or morning symptoms and patients with both
morning and night symptoms within the GOLD A,B,C,D categories.
Figure 2. Percentages of patients with no morning and night
symptoms, only night or morning symptoms and patients with both
morning and night symptoms within the GOLD 1,2,3,4 categories.
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primary care, and therefore these ﬁndings may be applicable to a
wider population. However, as a cross-sectional study, there is a
lack of ability to show cause and effect. The longitudinal analysis
provides valuable additional information.
Our study used the ACQ questions to assess morning and night
symptoms. This may be considered invalid because the ACQ is not
designed nor validated for the use in COPD patients. However, no
validated instrument exists that assesses both morning and night
symptoms in COPD patients, and all patients completed both
questionnaires in the study at baseline, as the diagnosis had not
yet been established. Up until now, studies conducted to assess
those symptoms used different tools, questionnaires,20 patient
record forms,7,18 the clinical symptom questionnaire,15 inter-
views7,11,12 or the a ‘Night-time/Morning and Day-time Symptoms
of COPD questionnaire’.13 Questions similar to the ACQ questions
have been used in the majority of these studies to assess morning
and night symptoms. Some examples are shown in the study by
Kim et al.15 ‘When were your symptoms the most troublesome for
you? On waking / In the morning / In the afternoon / In the
evening / At night’ and in the study by Lange et al.20 ‘do you
sometimes wake up in the night because of breathlessness/
difﬁculties with breathing’? Nevertheless, we believe that these
possible limitations do not invalidate the results obtained.
Implications for future research, policy and practice
Symptom variability may be an additional sign that the disease is
not under control. Patients suffering more from morning and
night symptoms are at a higher risk of future exacerbations. A new
patient-reported outcome instrument, the Night-time Symptoms
of COPD Instrument (NiSCI), has been recently developed.29
However, unfortunately, to date no validated questionnaires that
measure both morning and night symptoms are available.
Data suggest that only a minority of patients adapt their
treatment in response to worsening of symptoms7 and that
patients are taking medications too late in the day to beneﬁt fully
from their potential effects.12,30 Further work is now warranted to
identify the periods in which the symptoms are more intense and
the medications that improve these morning or night symptoms.
Recently, in a meeting focusing on the night-time symptoms and
sleep disturbances of COPD patients, a panel of experts high-
lighted the lack of interest in clinical studies on these aspects and
suggested a call for action.6
Conclusions
Morning and night symptoms are common in COPD patients.
Patients with morning/night symptoms have on average poorer
lung function, higher CCQ scores, higher severity, are mostly
smokers and use more rescue inhalers; these ﬁndings are not
reﬂected in the current GOLD approach. Our study shows that
very few patients experience many morning or night symptoms
when the CCQ scores are low, suggesting that having morning/
night symptoms does not reﬂect a speciﬁc phenotype. Patients
using LAMA have less night symptoms, showing a possible
favourable effect. Severe morning symptoms increased the odds
of poor health status at follow-up. Morning and night symptoms
seemed to predict future exacerbations; however, baseline
exacerbations are the strongest predictors.
MATERIALS AND METHODS
Participants setting
We included the data from 2,269 COPD patients (57.8% male, 49.0%
current smokers, with a mean age of 65.3 ± 10.8 years) between 2007 and
2013, assessed by a primary care Asthma/COPD service31 that operates in
Table 4. Regression analyses with three different dependent variables, having an exacerbation, total CCQ score, FEV1 predicted, 10–17 months after
baseline (n= 346)
Predictor Risk factor OR 95% CI P value
Dependent variable: having an exacerbation, 10–17 months after baseline visit (n= 346)
Baseline exacerbation No 1
Yes 4.13 2.45-6.95 o0.000
Morning symptoms (ACQ question 2) No (ACQ= 0) 1
Moderate (ACQ:1–3) 1.24 0.60-2.56 NS
Severe (ACQ⩾ 4) 1.58 0.76-3.28 NS
Night symptoms (ACQ question 1) No (ACQ= 0) 1
Moderate (ACQ:1–3) 1.94 1.02-3.69 0.044
Severe (ACQ⩾ 4) 1.27 0.52-3.09 NS
Dependent variable: total CCQascore⩾ 1, 10–17 months after baseline visit (n = 345)
Baseline total CCQ score Low symptomatic (CCQo1) 1
High symptomatic (CCQ⩾ 1) 6.48 3.66-11.46 o0.000
Morning symptoms (ACQ question 2) No (ACQ= 0) 1
Moderate (ACQ:1–3) 2.75 1.33-5.70 0.006
Severe (ACQ⩾ 4) 12.22 4.76-31.39 o0.000
Night symptoms (ACQ question 1) No (ACQ= 0) 1
Moderate (ACQ:1–3) 1.99 1.01-3.91 0.047
Severe (ACQ⩾ 4) 2.63 0.81-8.56 NS
Predictor B s.e. t P value
Dependent variable: FEV1% predicted, 10–17 months after baseline visit (n=345)
Constant 7.45 2.44 3.06 0.002
Baseline FEV1% predicted 0.90 0.03 28.76 o0.000
Morning symptoms (ACQ question 2) − 0.01 0.63 − 0.01 NS
Night symptoms (ACQ question 1) − 0.75 0.52 −1.43 NS
Abbreviations: ACQ, Asthma Control Questionnaire; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in
1 s; CCQ, COPD Clinical Questionnaire; NS, not signiﬁcant; OR, odds ratio.
aClinical COPD Questionnaire.
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the Netherlands. In this service, a pulmonologist reviews patients for
general practitioners after assessment by the primary care laboratory. All
patients undergo a systematic assessment. The general practitioners
referred patients with respiratory complaints to the service (GP) for
diagnostic assessment. Pulmonologist diagnose with COPD, asthma,
asthma/COPD overlap, restrictive disease or diagnosis uncertain. We have
only included ‘pure’ COPD without overlap or a history of asthma in
this study.
In this study, we used anonymous assessment data. According to Dutch
regulations, a separate ethics committee approval is not required, because
routinely collected health-care data are used after anonymisation.
Spirometry-patients reported outcomes
Spirometry was performed including reversibility testing at baseline. All
patients’ reported outcomes were part of the regular assessment
procedure of the AC service. Patients, regardless of their current diagnosis,
ﬁlled in a history questionnaire containing questions about medication
use, exacerbations, age of onset, allergies, hyper-reactivity and family
history. In addition, the history questionnaire included the Asthma Control
Questionnaire (ACQ)32 and the Clinical COPD Questionnaire (CCQ).4
Therefore, our COPD patients had ACQ scores available.32 For the
assessment of morning and night symptoms, the ACQ question 2 (‘On
average, during the past week, how bad were your asthma symptoms
when you woke up in the morning?’) and question 1 (‘On average, during
the past week, how often were you woken by your asthma during the
night?’) were used.
Statistical analyses
IBM SPSS version 22 was used to analyse the data. Missing data were
scarce (o1%) and assumed to be missing at random and therefore not
imputed.
Descriptive analysis
We have described the prevalence of morning and night symptoms in our
COPD population along with a thorough description of our population in
terms of age, gender, age of onset, smoking status, severity of COPD,
symptoms, health status and medication use. We calculated correlations
between morning/ night symptoms and age, age of onset, CCQ,
exacerbations, wheezing and lung function. We categorised the ACQ
question 1 scores and ACQ question 2 scores into ‘No symptoms (ACQ= 0),’
‘Mild symptoms (ACQ= 1–3)’ and ‘Highly symptomatic (ACQ⩾ 4).’
Inferential analyses: cross-sectional differences
We based the cross-sectional analyses on baseline data from 2,369
patients. We tested cross-sectional baseline differences in patient
characteristics, COPD severity and symptoms between patients with
morning symptoms or/and night symptoms and patients without morning
or night symptoms with a t-test or Mann–Whitney U-test when we had
continuous variables. We used the χ2-test if the variable was discrete and
post hoc binomial regression to compare LAMA use in patients without
morning/night symptoms with patients in the other groups.
Inferential analyses: Longitudinal differences
Before GPs referred to the AC service, they indicated whether they wanted
to follow-up the patients themselves or whether patients should be
scheduled for yearly follow-up assessments by the AC service. We included
data from patients scheduled for the yearly follow-up assessment by the
AC service. We assessed these patients in 10 to 17 months after their
baseline visit (n= 445) and compared baseline results with follow-up data.
We also used multinomial logistic regression to examine whether morning
symptoms or night symptoms could predict the risk of an exacerbation or
poor health status (CCQ total score ⩾ 1, according to the GOLD
guidelines).1 We took into account, respectively, baseline exacerbation or
baseline health status. Through linear regression analysis, we assessed the
effect of morning/night symptoms on FEV1 decline.
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